Anwendung dihydrierter Mutterkornalkaloide (CCK 179 = Hydergin) bei peripheren Durchblutungsst�rungen und anderen sympathicotonen Krankheitsbildern. Versuch einer Analyse

Eichler, Oskar; Heinzel, J; Linder, F

doi:10.1007/bf01486792

Cited by 13 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The value of Hydergine in peripheral vascular disorders also has been the subject of several reports (7,(18)(19)(20)(21)(22)(23)(24)(25). In recent studies on causalgia, Hydergine has been injected intra-arterially into the extremities, or intravenously into other involved areas of the body.…”

Section: August 1960mentioning

confidence: 99%

Combined Vasodilator Therapy in Peripheral Vascular Diseases

Popkin¹

1960

J American Geriatrics Society

View full text Add to dashboard Cite

Section: August 1960mentioning

confidence: 99%

Combined Vasodilator Therapy in Peripheral Vascular Diseases

Popkin¹

1960

J American Geriatrics Society

View full text Add to dashboard Cite

“…using one or more of the hydrogenated ergot alkaloids include the use in the differential diagnosis of functional heart disturbances and organic heart disease (35), bronchial asthma (24), congestive glaucoma (36), hypertension (6,10,13,16,17), and peripheral vascular diseases (1,10,15,17,25,30). Its beneficial action in returning the coagulation time of the blood to normal in 4 cases of hemophilia (37) has also been reported.…”

mentioning

confidence: 99%

An Evaluation of Some Dihydrogenated Alkaloids of Ergot in the Management of Chronic Peripheral Vascular Diseases

Popkin

1951

Angiology

View full text Add to dashboard Cite

It is the purpose of this paper to report on the clinical evaluation of certain dihydrogenated alkaloids of ergot in the management of chronic peripheral vascular diseases. This study covered a 2 year period. The diseases treated were arteriosclerosis obliterans, thromboangiitis obliterans, vasospastic disorders comprising Raynaud's disease and Raynaud's syndrome and obstructive edema of the extremities. The following hydrogenated ergot alkaloids, dihydroergocristine (DCS 90), dihydroergocorinine (DHO 180) and dihydroergokryptine (DHK 135) were used in an equimixture known as CCK 1'79. j' This report augments an earlier publication by this author (1).Crude ergot has been used as a medicine for centuries. It was known early for its oxytocic properties. The fundamental studies were first made by Dale (2) in 1906 who recognized 2 active principles in ergot. The action of the first principle was a direct stimulation of smooth muscle including blood vessels; the action of the second was the inhibition of sympathetic activity. This sympatholytic effect was latent and completely overshadowed by the direct smooth muscle stimulating property. Several alkaloids were later isolated from ergot; namely, ergotamine, ergosine, ergocristine, ergokryptine, ergocornine and ergobasine. Stoll and Hoffman (3) in 1943 produced a new series of compounds by hydrogenating these alkaloids. Rothlin (4) demonstrated that hydrogenation decreased the toxicity of the natural alkaloids and increased the latent sympatholyticadrenolytic property with the result that this property dominated much of the pharmacological activity.Recent investigations have confirmed and added to our knowledge of the sympatholytic-adrenolytic property. Considerable literature (5-34) has accumulated concerning its actions in man and animals. Two sites of activity have been demonstrated, central and peripheral. The central action is complex; the major effects being due to an inhibition of the vasomotor center leading to a lowering of the vascular tone, peripheral vasodilatation and diminution of arterial tension. Other central effects reported are bradycardia, inhibition of the pressosensory reflexes and sedation. Its peripheral actions are chiefly latent adrenosympatholoytic upon functions stimulated by epinephrine and upon functions inhibited by epinephrine. These actions depend primarily upon the dosage and experimental animal used. Recent reports of favorable clinical activity in man at NORTH DAKOTA STATE UNIV LIB on June 26, 2015 ang.sagepub.com Downloaded from

show abstract

Krankheiten der Gefäße

Wollheim¹,

Zissler²

1960

Krankheiten Der Gefässe

View full text Add to dashboard Cite

Anwendung dihydrierter Mutterkornalkaloide (CCK 179 = Hydergin) bei peripheren Durchblutungsst�rungen und anderen sympathicotonen Krankheitsbildern. Versuch einer Analyse

Cited by 13 publications

References 5 publications

Combined Vasodilator Therapy in Peripheral Vascular Diseases

Combined Vasodilator Therapy in Peripheral Vascular Diseases

An Evaluation of Some Dihydrogenated Alkaloids of Ergot in the Management of Chronic Peripheral Vascular Diseases

Krankheiten der Gefäße

Contact Info

Product

Resources

About